-
我が国のワクチン発祥の地、
長崎から新たに始まるワクチン開発研究 -
-
Topics
新着情報
-
感染症疫学短期コース “Introduction to Infectious Disease Epidemiology and Modelling” を開催しました
Thursday 24 August 2023
-
感染症疫学短期コース “Introduction to Infectious Disease Epidemiology and Modelling” を開催しました
Thursday 24 August 2023
登録されている記事がありません。
About us
ワクチン研究開発拠点について
長崎大学感染症研究出島特区 ワクチン研究開発拠点は,「ワクチン開発のための世界トップレベル研究開発拠点の形成事業」に採択された4つのシナジー拠点の一つです。長崎大学がこれまで研究してきた高病原性病原体や熱帯性病原体を対象としたワクチン開発を推進し,人類の脅威となる感染症に対するワクチン開発を目指します。
Careers
公募・求人情報
-
現在募集中の公募・求人情報はありません。
Publications
研究業績
12924226
1
apa
5
default
desc
year
1
54
https://dida.nagasaki-u.ac.jp/dida_wp/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22CUU4UX2G%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lin%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-29%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELin%2C%20H.%2C%20Ngwe%20Tun%2C%20M.%20M.%2C%20Zin%2C%20Y.%20M.%20W.%2C%20Myint%2C%20K.%20T.%2C%20Khine%2C%20W.%20K.%2C%20Nwe%2C%20K.%20M.%2C%20Thant%2C%20A.%20A.%2C%20Shwe%2C%20T.%20T.%2C%20Mar%2C%20W.%2C%20Aye%2C%20K.%20S.%2C%20Aung%2C%20K.%20M.%2C%20Takamatsu%2C%20Y.%2C%20Aung%2C%20W.%20W.%2C%20Kyaw%2C%20Y.%20Y.%2C%20Urano%2C%20T.%2C%20Morita%2C%20K.%2C%20%26amp%3B%20Thu%2C%20H.%20M.%20%282025%29.%20Comparison%20of%20clinical%20and%20virological%20features%20in%20pediatric%20and%20adult%20dengue%20cases%20at%20Insein%20General%20Hospital%20during%20Myanmar%26%23x2019%3Bs%202022%20dengue%20season.%20%3Ci%3ETropical%20Medicine%20and%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E53%3C%5C%2Fi%3E%281%29%2C%2013.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs41182-025-00688-7%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs41182-025-00688-7%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20clinical%20and%20virological%20features%20in%20pediatric%20and%20adult%20dengue%20cases%20at%20Insein%20General%20Hospital%20during%20Myanmar%5Cu2019s%202022%20dengue%20season%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Htin%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mya%20Myat%22%2C%22lastName%22%3A%22Ngwe%20Tun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yin%20Mon%20Wint%22%2C%22lastName%22%3A%22Zin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khin%20Theingi%22%2C%22lastName%22%3A%22Myint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Win%20Kay%22%2C%22lastName%22%3A%22Khine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khine%20Mya%22%2C%22lastName%22%3A%22Nwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aye%20Aye%22%2C%22lastName%22%3A%22Thant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thin%20Thin%22%2C%22lastName%22%3A%22Shwe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Win%22%2C%22lastName%22%3A%22Mar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khin%20Sandar%22%2C%22lastName%22%3A%22Aye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khaing%20Moe%22%2C%22lastName%22%3A%22Aung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuki%22%2C%22lastName%22%3A%22Takamatsu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wah%20Wah%22%2C%22lastName%22%3A%22Aung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%20Yi%22%2C%22lastName%22%3A%22Kyaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takeshi%22%2C%22lastName%22%3A%22Urano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kouichi%22%2C%22lastName%22%3A%22Morita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hlaing%20Myat%22%2C%22lastName%22%3A%22Thu%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Myanmar%20is%20one%20of%20the%20countries%20in%20Southeast%20Asia%20where%20serious%20dengue%20outbreaks%20occur%20and%20Yangon%20is%20among%20the%20regions%20with%20the%20highest%20number%20of%20cases%20in%20the%20country.%20Many%20infections%20including%20dengue%20are%20common%20in%20Yangon%20during%20the%20rainy%20season%2C%20and%20co-infections%20may%20also%20occur.%20Adults%20are%20more%20likely%20than%20children%20to%20experience%20co-infections%20of%20dengue%20and%20other%20diseases.%20Although%20pediatric%20dengue%20has%20been%20studied%20in%20Yangon%20for%20decades%2C%20research%20on%20adult%20dengue%20is%20scant.%20Therefore%2C%20this%20study%20compared%20the%20clinical%20and%20virological%20characteristics%20of%20pediatric%20and%20adult%20dengue%20cases%20in%20Yangon.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20cross-sectional%20study%20was%20conducted%20at%20Insein%20General%20Hospital%20in%20Yangon%2C%20Myanmar%2C%20from%20June%20to%20September%202022.%20We%20recruited%20221%20suspected%20dengue%20patients%20%28134%20children%20and%2087%20adults%29%2C%20with%20or%20without%20other%20diseases%2C%20and%20tested%20their%20dengue%20serological%20markers%20using%20a%20serological%20method%20and%20their%20dengue%20virus%20%28DENV%29%20serotypes%20using%20conventional%20RT-PCR.%20Chi-squared%20and%20Fisher%5Cu2019s%20exact%20tests%20were%20conducted%20to%20assess%20significance.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20dengue%20non-structural%20protein-1%20antigen%20%28NS1Ag%29%20positivity%20was%2037%25%20in%20children%20and%2032%25%20in%20adults.%20DENV%20serotypes%20were%20identified%20in%2080%25%20of%20NS1Ag-positive%20patients.%20Among%20NS1Ag-positive%20cases%2C%20the%20DENV-1%20serotype%20predominated%20%2867%25%29%2C%20followed%20by%20DENV-2%20%2817%25%29%2C%20DENV-3%20%289%25%29%2C%20DENV-4%20%285%25%29%2C%20and%20mixed%20DENV-1%20and%20DENV-2%20%282%25%29%20serotypes.%20Shock%20was%20observed%20in%2014%25%20of%20children%20and%203%25%20of%20adults.%20Anti-dengue%20IgG%20antibody%20positivity%20was%20positively%20correlated%20with%20dengue%20shock.%20Three%20pediatric%20dengue%20cases%20%286%25%29%20also%20had%20other%20infections%20including%20bronchiolitis%2C%20ear%20infection%2C%20and%20diarrhea.%20Seven%20adult%20dengue%20cases%20%2825%25%29%20also%20had%20other%20diseases%20including%20advanced%20HIV%20infection%2C%20severe%20pneumonia%2C%20tonsillitis%2C%20thyroid%20disease%2C%20cholecystitis%2C%20drug%20poisoning%2C%20and%20thalassemia.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20serotype%20distribution%20and%20clinical%20presentations%20of%20pediatric%20and%20adult%20dengue%20cases%20were%20not%20significantly%20different%2C%20but%20adults%20were%20more%20likely%20to%20have%20dengue%20together%20with%20other%20diseases%20than%20children.%20This%20study%20provides%20information%20for%20the%20better%20management%20of%20febrile%20children%20and%20adults%20in%20hospital%20settings%20and%20provides%20a%20foundation%20for%20nationwide%20epidemiological%20studies%20on%20dengue%20serotypes%20and%20modifications%20of%20the%20national%20guidelines%20for%20dengue%20management%20in%20Myanmar.%22%2C%22date%22%3A%222025-01-29%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs41182-025-00688-7%22%2C%22ISSN%22%3A%221349-4147%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ftropmedhealth.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs41182-025-00688-7%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-02-03T00%3A16%3A04Z%22%7D%7D%2C%7B%22key%22%3A%226J5Z48P9%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jin%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJin%2C%20S.%2C%20Asakura%2C%20T.%20R.%2C%20Murayama%2C%20H.%2C%20Niyukuri%2C%20D.%2C%20Saila-Ngita%2C%20D.%2C%20Lim%2C%20J.%20T.%2C%20Endo%2C%20A.%2C%20%26amp%3B%20Dickens%2C%20B.%20L.%20%282025%29.%20%3Ci%3EVaccine%20demands%20to%20achieve%20outbreak%20control%20for%20MPXV%20Clade%20I%20with%20one-time%20mass%20campaign%20in%20sub-Saharan%20Africa%3A%20scenario-based%20modelling%20study%3C%5C%2Fi%3E.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.01.17.25320753%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.01.17.25320753%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22preprint%22%2C%22title%22%3A%22Vaccine%20demands%20to%20achieve%20outbreak%20control%20for%20MPXV%20Clade%20I%20with%20one-time%20mass%20campaign%20in%20sub-Saharan%20Africa%3A%20scenario-based%20modelling%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shihui%22%2C%22lastName%22%3A%22Jin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toshiaki%20R%22%2C%22lastName%22%3A%22Asakura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroaki%22%2C%22lastName%22%3A%22Murayama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Niyukuri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diafuka%22%2C%22lastName%22%3A%22Saila-Ngita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jue%20Tao%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akira%22%2C%22lastName%22%3A%22Endo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Borame%20L%22%2C%22lastName%22%3A%22Dickens%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Declining%20cross-protection%20from%20historical%20smallpox%20vaccination%20campaigns%20and%20persistent%20zoonotic%20reservoirs%20leave%20many%20sub-Saharan%20countries%20susceptible%20to%20mpox%20outbreaks.%20With%20millions%20of%20vaccine%20doses%20made%20available%20to%20the%20region%20since%20late%202024%2C%20estimating%20the%20country%20specific%20impact%20of%20one-time%20mass%20vaccination%20strategies%20is%20crucial%20for%20ongoing%20outbreaks%20and%20for%20other%20countries%20at%20future%20risk.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Methods%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20adapted%20a%20next%20generation%20matrix%20model%20to%20incorporate%20vaccination%20which%20was%20calibrated%20using%20mpox%20datasets%20from%20the%20Democratic%20Republic%20of%20Congo.%20We%20projected%20the%20effective%20reproduction%20number%2C%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20R%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20eff%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2C%20for%2047%20sub-Saharan%20countries%20from%202025%20to%202050%20under%20four%20transmission%20scenarios%20with%20different%20contributions%20of%20community%20vs%20sexual%20contacts%2C%20informed%20by%20Clade%20Ia%20and%20Ib%20outbreaks.%20We%20then%20calculated%20country-specific%20minimum%20vaccine%20coverages%20required%20for%20outbreak%20control%20and%20evaluated%20one-time%20age-specific%20mass%20vaccination%20strategies%20for%20reducing%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20R%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20eff%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Findings%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20For%20all%2047%20countries%2C%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20R%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20eff%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20s%20are%20projected%20to%20rise.%20At%20least%2020%20are%20estimated%20to%20require%20vaccination%20in%202025%2C%20and%2036%20in%202050%2C%20in%20the%20event%20of%20national%20outbreaks.%20For%20eleven%20clade%20I-affected%20countries%2C%20the%20minimum%20required%20coverage%20is%20estimated%20to%20range%20from%200%25%5Cu20134.8%25%20to%2014.5%25%5Cu201319.5%25%20in%202025%20with%20increasing%20sexual%20transmission%2C%20increasing%20to%200%25%5Cu201310.8%25%20and%2022.6%25%5Cu201326.0%25%20in%202050%2C%20respectively.%20The%20prioritised%20age%20group%20for%20vaccination%20shifts%20from%200%5Cu20134%20to%2020%5Cu201329%20with%20additional%20sexual%20transmission.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Interpretation%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20With%20diminishing%20smallpox-vaccination-induced%20immunity%2C%20increasing%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20R%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20eff%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20s%20and%20potential%20for%20persistent%20outbreaks%20are%20expected%20for%20mpox.%20Policymakers%20may%20face%20increasing%20vaccine%20demand%2C%20which%20will%20necessitate%20coordinated%20efforts%20to%20prioritise%20high-risk%20groups%20under%20supply%20constraints.%22%2C%22genre%22%3A%22%22%2C%22repository%22%3A%22%22%2C%22archiveID%22%3A%22%22%2C%22date%22%3A%222025-01-18%22%2C%22DOI%22%3A%2210.1101%5C%2F2025.01.17.25320753%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fmedrxiv.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1101%5C%2F2025.01.17.25320753%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-02-03T00%3A15%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22ZEMMGITQ%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Uemura%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EUemura%2C%20R.%2C%20Tanimura%2C%20S.%2C%20Yamaguchi%2C%20N.%2C%20Kuroiwa%2C%20R.%2C%20Andr%26%23xE9%3Bs%20Tsutsumi%2C%20G.%20T.%2C%20Fujikawa%2C%20T.%2C%20Soyano%2C%20K.%2C%20Takeda%2C%20K.%2C%20%26amp%3B%20Tanaka%2C%20Y.%20%282025%29.%20Expression%20Analysis%20of%20Heavy-Chain-Only%20Antibodies%20in%20Cloudy%20Catshark%20and%20Japanese%20Bullhead%20Shark.%20%3Ci%3EMarine%20Drugs%3C%5C%2Fi%3E%2C%20%3Ci%3E23%3C%5C%2Fi%3E%281%29%2C%2028.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmd23010028%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmd23010028%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expression%20Analysis%20of%20Heavy-Chain-Only%20Antibodies%20in%20Cloudy%20Catshark%20and%20Japanese%20Bullhead%20Shark%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reo%22%2C%22lastName%22%3A%22Uemura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susumu%22%2C%22lastName%22%3A%22Tanimura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nao%22%2C%22lastName%22%3A%22Yamaguchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryuichi%22%2C%22lastName%22%3A%22Kuroiwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%20Takashi%22%2C%22lastName%22%3A%22Andr%5Cu00e9s%20Tsutsumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toshiaki%22%2C%22lastName%22%3A%22Fujikawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%22%2C%22lastName%22%3A%22Soyano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kohsuke%22%2C%22lastName%22%3A%22Takeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshimasa%22%2C%22lastName%22%3A%22Tanaka%22%7D%5D%2C%22abstractNote%22%3A%22Heavy%20chain-only%20antibodies%20in%20sharks%20are%20called%20immunoglobulin%20new%20antigen%20receptors%20%28IgNAR%29%2C%20consisting%20of%20one%20variable%20region%20%28VNAR%29%20and%20five%20constant%20regions%20%28C1-C5%29.%20The%20variable%20region%20of%20IgNAR%20can%20be%20expressed%20as%20a%20monomer%20composed%20of%20a%20single%20domain%2C%20which%20has%20antigen%20specificity%20and%20is%20thus%20gaining%20attention%20as%20a%20next-generation%20antibody%20drug%20modality.%20In%20this%20study%2C%20we%20analyzed%20IgNAR%20of%20the%20cloudy%20catshark%20and%20Japanese%20bullhead%20shark%2C%20small%20demersal%20sharks%20available%20in%20the%20coastal%20waters%20of%20Japan.%20By%20analyzing%20the%20IgNAR%20gene%20sequence%20and%20comparing%20it%20with%20the%20constant%20regions%20of%20five%20other%20known%20shark%20species%2C%20high%20homology%20was%20observed%20in%20the%20C4%20region.%20Consequently%2C%20we%20expressed%20the%20recombinant%20protein%20of%20the%20C4%20domain%20from%20the%20cloudy%20catshark%20in%20E.%20coli%2C%20immunized%20rats%2C%20and%20produced%20antibodies.%20The%20obtained%20antiserum%20and%20mAbs%20recognized%20the%20C4%20recombinant%20protein%20of%20the%20cloudy%20catshark%2C%20but%20reacted%20minimally%20with%20the%20plasma%20of%20non-immunized%20cloudy%20catsharks%20and%20instead%20reacted%20with%20the%20plasma%20of%20Japanese%20bullhead%20sharks.%20The%20results%20of%20this%20study%20imply%20that%20the%20protein%20expression%20levels%20of%20IgNAR%20in%20cloudy%20catsharks%20may%20be%20relatively%20lower%20compared%20to%20those%20in%20Japanese%20bullhead%20sharks%2C%20however%2C%20this%20interpretation%20remains%20to%20be%20determined%20through%20further%20studies.%22%2C%22date%22%3A%222025-01-08%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fmd23010028%22%2C%22ISSN%22%3A%221660-3397%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F1660-3397%5C%2F23%5C%2F1%5C%2F28%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222025-02-03T00%3A14%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22HUUSSIZM%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mogasale%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMogasale%2C%20V.%20V.%2C%20Sinha%2C%20A.%2C%20John%2C%20J.%2C%20Hasan%20Farooqui%2C%20H.%2C%20Ray%2C%20A.%2C%20Chantler%2C%20T.%2C%20Mogasale%2C%20V.%2C%20Dhoubhadel%2C%20B.%20G.%2C%20Edmunds%2C%20W.%20J.%2C%20Clark%2C%20A.%2C%20%26amp%3B%20Abbas%2C%20K.%20%282024%29.%20Research%20priorities%20to%20support%20typhoid%20conjugate%20vaccine%20decision-making%20in%20India%3A%20evidence%20assessment%20and%20stakeholder%20survey.%20%3Ci%3EBMJ%20Public%20Health%3C%5C%2Fi%3E%2C%20%3Ci%3E2%3C%5C%2Fi%3E%282%29%2C%20e001089.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjph-2024-001089%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjph-2024-001089%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Research%20priorities%20to%20support%20typhoid%20conjugate%20vaccine%20decision-making%20in%20India%3A%20evidence%20assessment%20and%20stakeholder%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijayalaxmi%20V%22%2C%22lastName%22%3A%22Mogasale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anish%22%2C%22lastName%22%3A%22Sinha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%22%2C%22lastName%22%3A%22John%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Habib%22%2C%22lastName%22%3A%22Hasan%20Farooqui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arindam%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tracey%22%2C%22lastName%22%3A%22Chantler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vittal%22%2C%22lastName%22%3A%22Mogasale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhim%20Gopal%22%2C%22lastName%22%3A%22Dhoubhadel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%20John%22%2C%22lastName%22%3A%22Edmunds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaja%22%2C%22lastName%22%3A%22Abbas%22%7D%5D%2C%22abstractNote%22%3A%22Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20India%20has%20a%20high%20typhoid%20fever%20burden.%20In%202022%2C%20the%20National%20Technical%20Advisory%20Group%20on%20Immunisation%20recommended%20introducing%20typhoid%20conjugate%20vaccine%20%28TCV%29%20into%20the%20Universal%20Immunisation%20Programme.%20Our%20study%20aims%20to%20identify%20research%20priorities%20to%20support%20ongoing%20TCV%20decision-making%20in%20India.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20identified%2045%20evidence%20factors%20for%20TCV%20decision-making%20in%20India%20by%20adapting%20WHO%5Cu2019s%20Evidence-to-Recommendation%20framework.%20We%20assigned%20an%20evidence%20gap%20score%20for%20each%20evidence%20factor%20from%200%20%28low%29%20to%204%20%28high%29%20based%20on%20the%20availability%20and%20sufficiency%2C%20quality%2C%20breadth%20and%20applicability%20of%20evidence%20identified%20in%20a%20literature%20review%20%28end%20date%2030%20November%202023%29.%20We%20assigned%20each%20evidence%20factor%20an%20importance%20score%20based%20on%20the%20results%20of%20an%20online%20survey%20conducted%20among%20national%20immunisation%20stakeholders%20%28n%3D22%2C%201%20July%202023%5Cu201331%20October%202023%29%2C%20where%20they%20ranked%20the%20importance%20of%20seven%20WHO%5Cu2019s%20Evidence-to-Recommendation%20criteria%20and%20several%20evidence%20factors%20within%20them.%20We%20rescaled%20mean%20stakeholder%20rankings%20into%20importance%20scores%20from%200%20%28low%29%20to%204%20%28high%29.%20Finally%2C%20we%20added%20the%20evidence%20gap%20score%20to%20the%20importance%20score%20and%20used%20the%20overall%20scores%20to%20identify%20research%20priorities%20to%20support%20ongoing%20TCV%20decision-making%20in%20India.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20estimated%20the%20highest%20evidence%20priority%20scores%20for%20public%20perception%20of%20typhoid%20fever%2C%20vaccination%20budget%20impact%2C%20vaccine%20availability%2C%20socioeconomic%20impact%2C%20fiscal%20space%2C%20antimicrobial%20resistance%20tracking%2C%20typhoid%20fever%20mortality%2C%20public%20perception%20of%20TCV%2C%20immunisation%20managers%5Cu2019%20acceptance%20and%20vaccine%20schedule%20preferences%20among%20caregivers.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20By%20adapting%20WHO%5Cu2019s%20Evidence-to-Recommendation%20framework%20to%20the%20Indian%20context%2C%20we%20systematically%20identified%20several%20research%20priorities%20to%20support%20ongoing%20decision-making%20on%20TCV%20in%20India.%20These%20priorities%20will%20evolve%20as%20new%20research%20studies%20and%20questions%20emerge%20about%20the%20optimal%20scheduling%2C%20roll-out%20and%20implementation%20of%20TCV%20in%20India.%22%2C%22date%22%3A%2210%5C%2F2024%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjph-2024-001089%22%2C%22ISSN%22%3A%222753-4294%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbmjpublichealth.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fbmjph-2024-001089%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-12-11T04%3A14%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22DWRYRNR4%22%2C%22library%22%3A%7B%22id%22%3A12924226%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mogasale%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMogasale%2C%20V.%20V.%2C%20Sinha%2C%20A.%2C%20John%2C%20J.%2C%20Hasan%20Farooqui%2C%20H.%2C%20Ray%2C%20A.%2C%20Chantler%2C%20T.%2C%20Mogasale%2C%20V.%2C%20Gopal%20Dhoubhadel%2C%20B.%2C%20John%20Edmunds%2C%20W.%2C%20Clark%2C%20A.%2C%20%26amp%3B%20Abbas%2C%20K.%20%282024%29.%20Typhoid%20conjugate%20vaccine%20implementation%20in%20India%3A%20A%20review%20of%20supportive%20evidence.%20%3Ci%3EVaccine%3A%20X%3C%5C%2Fi%3E%2C%20%3Ci%3E21%3C%5C%2Fi%3E%2C%20100568.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jvacx.2024.100568%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jvacx.2024.100568%3C%5C%2Fa%3E%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Typhoid%20conjugate%20vaccine%20implementation%20in%20India%3A%20A%20review%20of%20supportive%20evidence%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijayalaxmi%20V.%22%2C%22lastName%22%3A%22Mogasale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anish%22%2C%22lastName%22%3A%22Sinha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacob%22%2C%22lastName%22%3A%22John%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Habib%22%2C%22lastName%22%3A%22Hasan%20Farooqui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arindam%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tracey%22%2C%22lastName%22%3A%22Chantler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vittal%22%2C%22lastName%22%3A%22Mogasale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhim%22%2C%22lastName%22%3A%22Gopal%20Dhoubhadel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W%22%2C%22lastName%22%3A%22John%20Edmunds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaja%22%2C%22lastName%22%3A%22Abbas%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2024%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jvacx.2024.100568%22%2C%22ISSN%22%3A%2225901362%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2590136224001414%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-11-01T00%3A18%3A26Z%22%7D%7D%5D%7D
Lin, H., Ngwe Tun, M. M., Zin, Y. M. W., Myint, K. T., Khine, W. K., Nwe, K. M., Thant, A. A., Shwe, T. T., Mar, W., Aye, K. S., Aung, K. M., Takamatsu, Y., Aung, W. W., Kyaw, Y. Y., Urano, T., Morita, K., & Thu, H. M. (2025). Comparison of clinical and virological features in pediatric and adult dengue cases at Insein General Hospital during Myanmar’s 2022 dengue season. Tropical Medicine and Health, 53(1), 13. https://doi.org/10.1186/s41182-025-00688-7
Jin, S., Asakura, T. R., Murayama, H., Niyukuri, D., Saila-Ngita, D., Lim, J. T., Endo, A., & Dickens, B. L. (2025). Vaccine demands to achieve outbreak control for MPXV Clade I with one-time mass campaign in sub-Saharan Africa: scenario-based modelling study. https://doi.org/10.1101/2025.01.17.25320753
Uemura, R., Tanimura, S., Yamaguchi, N., Kuroiwa, R., Andrés Tsutsumi, G. T., Fujikawa, T., Soyano, K., Takeda, K., & Tanaka, Y. (2025). Expression Analysis of Heavy-Chain-Only Antibodies in Cloudy Catshark and Japanese Bullhead Shark. Marine Drugs, 23(1), 28. https://doi.org/10.3390/md23010028
Mogasale, V. V., Sinha, A., John, J., Hasan Farooqui, H., Ray, A., Chantler, T., Mogasale, V., Dhoubhadel, B. G., Edmunds, W. J., Clark, A., & Abbas, K. (2024). Research priorities to support typhoid conjugate vaccine decision-making in India: evidence assessment and stakeholder survey. BMJ Public Health, 2(2), e001089. https://doi.org/10.1136/bmjph-2024-001089
Mogasale, V. V., Sinha, A., John, J., Hasan Farooqui, H., Ray, A., Chantler, T., Mogasale, V., Gopal Dhoubhadel, B., John Edmunds, W., Clark, A., & Abbas, K. (2024). Typhoid conjugate vaccine implementation in India: A review of supportive evidence. Vaccine: X, 21, 100568. https://doi.org/10.1016/j.jvacx.2024.100568